Ursula A. Matulonis, MD | Authors

Articles

Phase II Results for Niraparib in Heavily Pretreated Patients With Ovarian Cancer

June 05, 2018

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses results from the phase II open-label, single-arm QUADRA study evaluating niraparib in patients with relapsed ovarian cancer who have received ≥3 prior chemotherapy regimens during the 2018 ASCO Annual Meeting.

Dr. Matulonis Discusses Mirvetuximab Soravtansine Plus Pembrolizumab in Ovarian Cancer

March 30, 2018

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha-targeting antibody-drug conjugate, with pembrolizumab (Keytruda) in patients with platinum-resistant epithelial ovarian cancer.

Toxicities Associated with PARP Inhibitors in Ovarian Cancer

August 02, 2017

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the toxicities that are associated with PARP inhibitors in ovarian cancer.